Please login to the form below

Not currently logged in
Email:
Password:

GSK cues up regulatory filings for relapsing malaria drug

60% of patients on tafenoquine combination remained relapse-free for six months

parasite

Armed with new phase III data, GlaxoSmithKline is planning regulatory filings for its one-dose antimalarial tafenoquine, which is designed to prevent relapses in patients infected with the parasite.

The new data shows that a single 300mg dose of tafenoquine - given alongside a three-day regimen of the older antimalarial chloroquine - can cut the chances of relapse in patients infected with the Plasmodium vivax parasite significantly.

GSK is developing the drug with the non-profit Medicines for Malaria Venture (MMV) as an alternative to primaquine, which is currently the only drug for relapsing forms of malaria but needs to be given over a 14-day period. Primaquine can cause serious side effects in some patients, with some evidence that resistance is developing to the drug.

"One of the greatest challenges for patients with P vivax malaria is preventing relapses," said GSK's president of R&D Patrick Vallance. "Being able to treat patients with a single dose of medicine would be an important step forward in ensuring efficacious treatment, thereby reducing the risk of relapse, particularly in areas with very limited healthcare infrastructure."

In the DETECTIVE trial, 60% of patients on tafenoquine plus chloroquine were relapse-free over a six-month follow-up period, compared to 26% of the placebo plus chloroquine group. A third arm received the standard primaquine plus chloroquine regimen, with 64% of patients relapse-free at six months.

A second trial called GATHER showed that there was little difference between tafenoquine and primaquine on levels of haemoglobin - the oxygen-carrying molecule in the blood. The trial uses haemoglobin level as a biomarker for haemolysis, the destruction of red blood cells, which is a recognised side effect with primaquine.

P vivax is one of several species of Plasmodium parasite known to cause malaria, and is the form most likely to lie dormant in the liver, periodically reactivating to cause relapses in the disease that can leave patients incapacitated for three days or more. It causes around 8.5m clinical infections every year according to the World Health Organization.

"Without treatment to eliminate the dormant form of the parasite, patients live with the disease, never knowing when it will relapse and when its debilitating symptoms will return," commented MMV chief executive David Reddy.

"Not only could single-dose tafenoquine help to put a stop to the relapse for individual patients but it could also help make malaria elimination a real possibility in P vivax endemic countries."

GSK is also developing a four-dose vaccine for malaria - RTS,S/AS01 - that has shown 31-56% protective efficacy in phase III trials and is now heading for pilot deployment in Ghana, Kenya and Malawi next year. The vaccine targets P falciparum, the most deadly malaria parasite globally and the most prevalent form in Africa.

Article by
Phil Taylor

14th June 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...